We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$2.53B
$10.3M 0.09%
+11,462
New +$6.78M
LGND icon
52
Ligand Pharmaceuticals
LGND
$5.71B
$10M 0.09%
117,638
– –
STML
53
DELISTED
Stemline Therapeutics, Inc.
STML
$9.88M 0.09%
633,497
– –
RIGL icon
54
Rigel Pharmaceuticals
RIGL
$857M
$9.77M 0.08%
251,888
– –
CBIO
55
Crescent Biopharma
CBIO
$637M
$9.46M 0.08%
5,633
– –
QURE icon
56
uniQure
QURE
$3.36B
$9.45M 0.08%
+482,557
New +$7.35M
ITCI
57
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.82M 0.08%
609,166
– –
ACHN
58
DELISTED
Achillion Pharmaceuticals
ACHN
$8.23M 0.07%
2,856,637
+1,000,000
+54% +$3.63M
ALKS icon
59
Alkermes
ALKS
$8.11B
$8.22M 0.07%
150,251
– –
LUMO
60
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$8.17M 0.07%
111,919
– –
AGIO icon
61
Agios Pharmaceuticals
AGIO
$1.98B
$7.36M 0.06%
128,666
– –
CFRX
62
DELISTED
ContraFect Corporation
CFRX
$7.22M 0.06%
8,941
– –
XLRN
63
DELISTED
Acceleron Pharma
XLRN
$6.96M 0.06%
163,900
– –
MGNX icon
64
MacroGenics
MGNX
$261M
$6.91M 0.06%
363,676
– –
VNDA icon
65
Vanda Pharmaceuticals
VNDA
$319M
$6.44M 0.06%
423,884
– –
SYRE icon
66
Spyre Therapeutics
SYRE
$9.39B
$6.16M 0.05%
45,515
– –
TTPH
67
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$5.89M 0.05%
46,750
– –
ADMS
68
DELISTED
Adamas Pharmaceuticals
ADMS
$5.85M 0.05%
172,630
– –
NBRV
69
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$5.61M 0.05%
3,753
– –
SYRS
70
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.59M 0.05%
57,484
– –
ALBO
71
DELISTED
Albireo Pharma Inc
ALBO
$5.12M 0.04%
200,000
– –
FSTX
72
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$5.01M 0.04%
93,286
– –
LJPC
73
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.98M 0.04%
154,675
– –
GNMX
74
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.87M 0.04%
4,055,142
-491,284
-11% -$671K
CMTA
75
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$4.75M 0.04%
250,000
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2017 Portfolio in Review

As of Q4 2017, Julian Baker held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Julian Baker's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Julian Baker's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Julian Baker fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Julian Baker's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Julian Baker opened 8 new positions and closed 5 in Q4 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.